NO306893B1 - Frysetörket doseringsform av ondansetron-blanding og anvendelse derav - Google Patents

Frysetörket doseringsform av ondansetron-blanding og anvendelse derav

Info

Publication number
NO306893B1
NO306893B1 NO972325A NO972325A NO306893B1 NO 306893 B1 NO306893 B1 NO 306893B1 NO 972325 A NO972325 A NO 972325A NO 972325 A NO972325 A NO 972325A NO 306893 B1 NO306893 B1 NO 306893B1
Authority
NO
Norway
Prior art keywords
ondansetron
freeze
dosage form
mixture
dried dosage
Prior art date
Application number
NO972325A
Other languages
English (en)
Norwegian (no)
Other versions
NO972325D0 (no
NO972325L (no
Inventor
Ian Keith Winterborn
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO306893(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of NO972325D0 publication Critical patent/NO972325D0/no
Publication of NO972325L publication Critical patent/NO972325L/no
Publication of NO306893B1 publication Critical patent/NO306893B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Fertilizers (AREA)
NO972325A 1994-11-22 1997-05-21 Frysetörket doseringsform av ondansetron-blanding og anvendelse derav NO306893B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9423511A GB9423511D0 (en) 1994-11-22 1994-11-22 Compositions
PCT/EP1995/004550 WO1996015785A1 (en) 1994-11-22 1995-11-20 Freeze-dried ondansetron compositions

Publications (3)

Publication Number Publication Date
NO972325D0 NO972325D0 (no) 1997-05-21
NO972325L NO972325L (no) 1997-05-22
NO306893B1 true NO306893B1 (no) 2000-01-10

Family

ID=10764757

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972325A NO306893B1 (no) 1994-11-22 1997-05-21 Frysetörket doseringsform av ondansetron-blanding og anvendelse derav

Country Status (30)

Country Link
US (2) US5955488A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0793495B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3001264B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR970706814A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1080118C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE193444T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU704160B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE1010250A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9509808A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY2166B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ285250B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69517332T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0793495T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2147309T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI119355B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2727016B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB9423511D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3033937T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU226891B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL116084A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1282352B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9703735A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO306893B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ296982A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL181179B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT793495E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2159614C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW398976B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1996015785A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA959821B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
EP1952802A3 (en) * 1997-10-01 2009-06-17 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
EP1246668B1 (en) * 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
RU2162847C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона и его фармацевтически приемлемых солей
EP1339707A2 (en) * 2000-10-30 2003-09-03 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
ES2288606T3 (es) * 2002-04-29 2008-01-16 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Procedimiento para preparar 1,2,3,9-tetrahidro-9-metil-3-((2-metil-1h-imidazol-1-il)metil)-4h-carbazol-4-ona.
KR20040104677A (ko) * 2002-04-30 2004-12-10 비오갈 기오기스제르갸르 알티. 신규의 온단세트론 결정 형태, 그 제조 방법, 그 신규의결정 형태를 함유하는 약학 조성물 및 이들을 이용한구역질 치료 방법
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
WO2004045615A1 (en) * 2002-11-15 2004-06-03 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
WO2005040123A1 (en) * 2003-10-10 2005-05-06 Synhton B. V. Solid-state montelukast
EP1709053B1 (en) * 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
JP2008509226A (ja) * 2004-05-24 2008-03-27 ジェンボールト コーポレイション 回収可能な形式での安定なタンパク質保管および安定な核酸保管
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
EP1919923A1 (en) * 2005-08-17 2008-05-14 Synthon B.V. A process for making olanzapine form i
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR057908A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast e intermediarios del mismo
CN101432267A (zh) * 2006-03-17 2009-05-13 斯索恩有限公司 孟鲁司特金刚烷胺盐
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
CA2665841C (en) 2006-10-09 2016-04-05 Charleston Laboratories, Inc. Pharmaceutical compositions
DK1940366T3 (da) * 2006-10-24 2009-06-29 Helsinn Healthcare Sa Blöde kapsler, der omfatter palonosetron-hydrochlorid, som har forbedret stabilitet og biotilgængelighed
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
RU2363463C1 (ru) * 2007-11-14 2009-08-10 Федеральное государственное унитарное предприятие Научно-производственный центр "Фармзащита" Федерального медико-биологического агентства Лекарственное средство
WO2009089494A2 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
EP2276739A1 (en) * 2008-04-25 2011-01-26 Synthon B.V. Process for making montelukast intermediates
ES2432618T3 (es) * 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
HRP20180531T1 (hr) * 2009-05-20 2018-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonisti serotoninskog 5-ht3 receptora za uporabu u liječenju površina vestibularnih lezija
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
PL3442537T3 (pl) 2016-04-14 2024-07-15 Sensorion (+)-azasetron do zastosowania w leczeniu zaburzeń ucha

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3275121D1 (en) * 1981-12-11 1987-02-19 Wyeth John & Brother Ltd Process for preparing solid shaped articles
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
GB8917556D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
JPH0648960A (ja) * 1990-02-22 1994-02-22 Glaxo Group Ltd 医 薬
US5046618A (en) * 1990-11-19 1991-09-10 R. P. Scherer Corporation Child-resistant blister pack

Also Published As

Publication number Publication date
HUT77886A (hu) 1998-09-28
AU704160B2 (en) 1999-04-15
GB2295318A (en) 1996-05-29
NZ296982A (en) 1998-06-26
DE69517332T2 (de) 2000-11-30
GR3033937T3 (en) 2000-11-30
ITRM950762A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-11-20
HU226891B1 (en) 2010-01-28
HK1009591A1 (en) 1999-06-04
FR2727016B1 (fr) 1998-04-03
FR2727016A1 (fr) 1996-05-24
GB2295318B (en) 1998-10-28
BR9509808A (pt) 1997-10-21
FI119355B (fi) 2008-10-31
CN1080118C (zh) 2002-03-06
CN1171741A (zh) 1998-01-28
CZ285250B6 (cs) 1999-06-16
US6063802A (en) 2000-05-16
RU2159614C2 (ru) 2000-11-27
IL116084A0 (en) 1996-01-31
DE69517332D1 (de) 2000-07-06
ITRM950762A1 (it) 1997-05-20
IL116084A (en) 2000-01-31
AU4173996A (en) 1996-06-17
EP0793495A1 (en) 1997-09-10
PL181179B1 (pl) 2001-06-29
BE1010250A3 (fr) 1998-04-07
CY2166B1 (en) 2002-08-23
JPH10508864A (ja) 1998-09-02
TW398976B (en) 2000-07-21
CZ154997A3 (en) 1997-10-15
NO972325D0 (no) 1997-05-21
US5955488A (en) 1999-09-21
WO1996015785A1 (en) 1996-05-30
MX9703735A (es) 1998-07-31
ZA959821B (en) 1996-07-31
KR970706814A (ko) 1997-12-01
FI972167A0 (fi) 1997-05-21
IT1282352B1 (it) 1998-03-20
FI972167L (fi) 1997-05-21
GB9423511D0 (en) 1995-01-11
EP0793495B1 (en) 2000-05-31
PT793495E (pt) 2000-10-31
NO972325L (no) 1997-05-22
DK0793495T3 (da) 2000-10-09
ATE193444T1 (de) 2000-06-15
ES2147309T3 (es) 2000-09-01
PL320295A1 (en) 1997-09-15
GB9523667D0 (en) 1996-01-24
JP3001264B2 (ja) 2000-01-24

Similar Documents

Publication Publication Date Title
NO306893B1 (no) Frysetörket doseringsform av ondansetron-blanding og anvendelse derav
DE69518767D1 (de) Ondasetronhaltige oral anzuwendende arzneimittel
AP1637A (en) Celecoxib compositions.
MY138227A (en) Valdecoxib compositions
MY133423A (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
IS4407A (is) Notkun samsetningarafurðar sem inniheldur samkeppnishæf prógesterónmótlyf og gestagen til framleiðslu á læknislyfi til meðhöndlunar á legslímuvillu eða bandvefsvöðvahnútum í legi
AR037239A1 (es) Composicion de valdecoxib de desintegracion intraoral, proceso para su preparacion, tableta que se obtiene y el uso de dicha composicion en la preparacion de un medicamento.
CA2205600A1 (en) Freeze-dried ondansetron compositions

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXOSMITHKLINE INC, CA

MK1K Patent expired